Black Rock Inc. Bio Atla, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCAB
# of Institutions
45Shares Held
12.3MCall Options Held
20.3KPut Options Held
1.2K-
Acorn Capital Advisors, LLC New York, NY4.03MShares$1.65 Million0.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.82MShares$745,3800.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$563,3710.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$305,3810.0% of portfolio
-
Morgan Stanley New York, NY596KShares$244,1900.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $14.9M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...